X4 Pharmaceuticals, Inc.
XFOR
$0.19
$0.00281.50%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -8.52% | -140.40% | 275.47% | -170.60% | -729.93% |
| Total Depreciation and Amortization | 2.25% | 37.63% | 212.90% | 0.00% | -40.38% |
| Total Amortization of Deferred Charges | 3.61% | -6.28% | -18.50% | 2.42% | 2.06% |
| Total Other Non-Cash Items | 33.51% | 103.15% | -877.51% | 541.66% | 84.07% |
| Change in Net Operating Assets | 172.09% | -258.30% | -49.86% | 139.01% | -251.36% |
| Cash from Operations | 3.05% | -12.40% | 9.88% | -21.08% | -33.22% |
| Capital Expenditure | 55.43% | 31.34% | -127.12% | -68.57% | -337.50% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 45.82% | -97.86% | -52.08% | -9.69% | 6.82% |
| Cash from Investing | 45.88% | -116.45% | 1,920.03% | -10.12% | 6.28% |
| Total Debt Issued | -- | -100.00% | -- | -- | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | 100.00% |
| Issuance of Common Stock | -- | -100.00% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Financing | -- | -100.00% | -- | -- | -99.54% |
| Foreign Exchange rate Adjustments | -247.88% | 1,016.67% | 69.49% | -146.46% | 276.39% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 16.21% | -157.42% | 322.50% | -20.47% | -566.86% |